Rapid antibody selection by mRNA display on a microfluidic chip by Tabata, Noriko et al.
Published online 30 March 2009 Nucleic Acids Research, 2009, Vol. 37, No. 8 e64
doi:10.1093/nar/gkp184
Rapid antibody selection by mRNA display on a
microfluidic chip
Noriko Tabata, Yuko Sakuma, Yumiko Honda, Nobuhide Doi, Hideaki Takashima,
Etsuko Miyamoto-Sato and Hiroshi Yanagawa*
Department of Biosciences and Informatics, Keio University, 3-14-1 Hiyoshi, Kohoku-ku, Yokohama 223-8522,
Japan
Received January 13, 2009; Revised March 4, 2009; Accepted March 8, 2009
ABSTRACT
In vitro antibody-display technologies are powerful
approaches for isolating monoclonal antibodies
from recombinant antibody libraries. However,
these display techniques require several rounds of
affinity selection which is time-consuming. Here, we
combined mRNA display with a microfluidic system
for in vitro selection and evolution of antibodies and
achieved ultrahigh enrichment efficiency of 10
6-
to 10
8-fold per round. After only one or two rounds
of selection, antibodies with high affinity and speci-
ficity were obtained from naı ¨ve and randomized
single-chain Fv libraries of ~10
12 molecules.
Furthermore, we confirmed that not only protein–
protein (antigen–antibody) interactions, but also
protein–DNA and protein–drug interactions were
selected with ultrahigh efficiencies. This method
will facilitate high-throughput preparation of anti-
bodies and identification of protein interactions in
proteomic and therapeutic fields.
INTRODUCTION
Rapid preparation of monoclonal antibodies with high
aﬃnity and speciﬁcity is required in diverse ﬁelds from
fundamental molecular and cellular biology to drug dis-
covery and diagnosis (1). In addition to classical hybrid-
oma technology, in vitro antibody-display technologies
(2–7) are powerful approaches for isolating single-chain
Fv (scFv) antibodies from recombinant antibody libraries.
However, these display techniques require several rounds
of aﬃnity selection (typically, library size is 10
7–10
12,
while enrichment eﬃciency is 10- to 10
3-fold per round).
Recently, microﬂuidic systems have been developed
for high-throughput protein analysis (8), because they
oﬀer the advantages of very low sample volumes, rapid
analysis and automated recovery of captured analytes
for further characterization. However, there has been
little attempt to combine microﬂuidic systems with
in vitro antibody-display technologies so far. Previously
we have developed an mRNA display system named
in vitro virus (IVV) (9), in which an in vitro-translated
full-length protein (phenotype) is covalently attached
to its encoding mRNA (genotype) through puromycin
(9–11). Here, we show that a microﬂuidic system can
be applied to the mRNA display selection of naı¨ve and
randomized scFv libraries, unexpectedly resulting in ultra-
high eﬃciency of scFv selection.
MATERIALS AND METHODS
Preparation of antigen proteins
Recombinant p53 protein was purchased from Active
Motif, and was diluted with a provided buﬀer (20mM
Tris–HCl, pH 8.0, 20% glycerol, 100mM KCl, 0.2mM
EDTA and 1mM DTT).
All primer sequences used for PCR are listed in Table 1.
Full-length ORFs corresponding to p53 and MDM2
were ampliﬁed by PCR from cDNAs with KOD-plus
DNA polymerase (Toyobo) using primers p53-NT1 and
p53-R-NT02 for p53 or primers MDM2-F and MDM2-R
for MDM2 (24 cycles of 30s at 948C, 30s at 588C and
2min at 688C). The PCR product was separated on 1%
low melting temperature agarose gel (Sigma), and gel-
puriﬁed using a Wizard PCR preps DNA puriﬁcation
kit (Promega). To add a His-tag sequence, the puriﬁed
MDM2 DNA was reampliﬁed by PCR with KOD-plus
DNA polymerase using primers CACC-MDM2-F and
MDM2-His10R. The PCR product was gel-puriﬁed as
described above.
In order to attach the antigens on a streptavidin-
conjugated solid resin, an ELISA plate or a sensor chip,
a Bio-tag sequence capable of attaching biotin in
Escherichia coli was introduced at the C-terminus of
p53 and MDM2. The Bio-tag sequence encoding a 72
amino acid peptide from oxaloacetate decarboxylase of
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BioEase
TM plasmid (Invitrogen) using primers F-Bio
and R-Bio. The PCR product was agarose gel-puriﬁed.
To add the Bio-tag, the puriﬁed p53 or MDM2 gene frag-
ment described above was mixed with the Bio-tag frag-
ment, and was reampliﬁed by PCR (100ml) with 5U of
KOD-plus DNA polymerase using CACC-p53-NT01
primer (3pmol), R-Bio primer (3pmol) and p53-Bio-link
oligonucleotide (0.1pmol) for p53, or CACC-MDM2-F
primer (3pmol), R-Bio primer (3pmol) and MDM2-Bio-
link oligonucleotide (0.1pmol) for MDM2 (8–12 cycles of
30s at 948C, 30s at 588C and 2min at 688C).
The resulting PCR products (MDM2-His-tag, p53-
Bio-tag and MDM2-Bio-tag) were gel-puriﬁed and then
cloned into the vector pET101/D-TOPO (Invitrogen)
using One Shot TOP 10 chemically competent E. coli
cells (Invitrogen). The orientation and sequence of the
cloned genes were veriﬁed by sequencing the isolated plas-
mids. The plasmids were then used to transform E. coli
BL21Star (DE3) One Shot cells (Invitrogen). The trans-
formed cells were cultured at 378C in 400ml of TB
medium containing 100mg/ml carbenicillin (Sigma) until
the OD660 reached 0.5–0.6, then isopropylthio-ß-D-galac-
toside (Nacalai tesque) was added to a ﬁnal concentration
of 1mM, and the cells were harvested 4–6h later.
For puriﬁcation of proteins, the cells were collected by
centrifugation, and resuspended in 20ml of TBS (20mM
Table 1. Oligonucleotide primers used for PCR
Primer name Sequences
p53-NT1 ATGGAGGAGCCGCAGTCAG
p53-R-NT02 GTCTGAGTCAGGCCCTTCTGTCTTG
MDM2-F ATGTGCAATACCAACATGTCTGTGTCTACCGATGGTGCT
MDM2-R GGGGAAATAAGTTAGCACAATCATTTGAATTGGTTGTCT
ACATACTGG
CACC
-MDM2-F
CACCATGTGCAATACCAACATGTCTGTGTCTACCG
MDM2-
His10R
CTATCAATGGTGGTGATGATGGTGATGGTGATGATGGG
GGAAATAAGTTAGCACAATCATTTGAATTGG
F-Bio GGCGCCGGCACCCCGGTGAC
R-Bio CGCCAGGGTCATCAGGGTGT
CACC-
p53-NT01
CACCATGGAGGAGCCGCAGTCAG
p53-Bio-link CAAGACAGAAGGGCCTGACTCAGACGGCGCCGGCACCC
CGGTGAC
MDM2-
Bio-link
GACAACCAATTCAAATGATTGTGCTAACTTATTTCCCC
GGCGCCGGCACCCCGGTGAC
MulgG1/2
forward
CTGGACAGGGATCCAGAGTTCCA
MulgG3
forward
CTGGACAGGGCTCCATAGTTCCA
MuCK
forward
CTCATTCCTGTTGAAGCTCTTGAC
HB Primers
HB1 GACTGGTGGACAGCAAATGGGTGAKGTRMAGCTTCAGGAGTC
HB2 GACTGGTGGACAGCAAATGGGTGAGGTBCAGCTBCAGCAGTC
HB3 GACTGGTGGACAGCAAATGGGTCAGGTGCAGCTGAAGSASTC
HB4 GACTGGTGGACAGCAAATGGGTGAGGTCCARCTGCAACARTC
HB5 GACTGGTGGACAGCAAATGGGTCAGGTYCAGCTBCAGCARTC
HB6 GACTGGTGGACAGCAAATGGGTCAGGTYCARCTGCAGCAGTC
HB7 GACTGGTGGACAGCAAATGGGTCAGGTCCACGTGAAGCAGTC
HB8 GACTGGTGGACAGCAAATGGGTGAGGTGAASSTGGTGGAATC
HB9 GACTGGTGGACAGCAAATGGGTGAVGTGAWGYTGGTGGAGTC
HB10 GACTGGTGGACAGCAAATGGGTGAGGTGCAGSKGGTGGAGTC
HB11 GACTGGTGGACAGCAAATGGGTGAKGTGCAMCTGGTGGAGTC
HB12 GACTGGTGGACAGCAAATGGGTGAGGTGAAGCTGATGGARTC
HB13 GACTGGTGGACAGCAAATGGGTGAGGTGCARCTTGTTGAGTC
HB14 GACTGGTGGACAGCAAATGGGTGARGTRAAGCTTCTCGAGTC
HB15 GACTGGTGGACAGCAAATGGGTGAAGTGAARSTTGAGGAGTC
HB16 GACTGGTGGACAGCAAATGGGTCAGGTTACTCTRAAAGWGTSTG
HB17 GACTGGTGGACAGCAAATGGGTCAGGTCCAACTVCAGCARCC
HB18 GACTGGTGGACAGCAAATGGGTGATGTGAACTTGGAAGTGTC
HB19 GACTGGTGGACAGCAAATGGGTGAGGTGAAGGTCATCGAGTC
LB Primers
LB1 GTGGCAGCATTGAGGGTCGCGAYATCCAGCTGACTCAGCC
LB2 GTGGCAGCATTGAGGGTCGCGAYATTGTTCTCWCCCAGTC
LB3 GTGGCAGCATTGAGGGTCGCGAYATTGTGMTMACTCAGTC
LB4 GTGGCAGCATTGAGGGTCGCGAYATTGTGYTRACACAGTC
LB5 GTGGCAGCATTGAGGGTCGCGAYATTGTRATGACMCAGTC
LB6 GTGGCAGCATTGAGGGTCGCGAYATTMAGATRAMCCAGTC
LB7 GTGGCAGCATTGAGGGTCGCGAYATTCAGATGAYDCAGTC
LB8 GTGGCAGCATTGAGGGTCGCGAYATYCAGATGACACAGAC
LB9 GTGGCAGCATTGAGGGTCGCGAYATTGTTCTCAWCCAGTC
LB10 GTGGCAGCATTGAGGGTCGCGAYATTGWGCTSACCCAATC
LB11 GTGGCAGCATTGAGGGTCGCGAYATTSTRATGACCCARTC
LB12 GTGGCAGCATTGAGGGTCGCGAYRTTKTGATGACCCARAC
LB13 GTGGCAGCATTGAGGGTCGCGAYATTGTGATGACBCAGKC
LB14 GTGGCAGCATTGAGGGTCGCGAYATTGTGATAACYCAGGA
LB15 GTGGCAGCATTGAGGGTCGCGAYATTGTGATGACCCAGWT
LB16 GTGGCAGCATTGAGGGTCGCGAYATTGTGATGACACAACC
LB17 GTGGCAGCATTGAGGGTCGCGAYATTTTGCTGACTCAGTC
LB  GTGGCAGCATTGAGGGTCGCGATGCTGTTGTGACTCAGCAATC
HF Primers
HF1 GATGGCCGAGACGTTTTGGCCGAGGAAACGGTGACCGTGGT
HF2 GATGGCCGAGACGTTTTGGCCGAGGAGACTGTGAGAGTGGT
(continued)
Table 1. Continued
Primer name Sequences
HF3 GATGGCCGAGACGTTTTGGCCGCAGAGACAGTGACCAGAGT
HF4 GATGGCCGAGACGTTTTGGCCGAGGAGACGGTGACTGAGGT
LF Primers
LF1 CTTGTCGTCGTCGTCCTTGTAGTCACGTTTGATTTCCAGCTTGG
LF2 CTTGTCGTCGTCGTCCTTGTAGTCACGTTTTATTTCCAGCTTGG
LF3 CTTGTCGTCGTCGTCCTTGTAGTCACGTTTTATTTCCAACTTTG
LF4 CTTGTCGTCGTCGTCCTTGTAGTCACGTTTCAGCTCCAGCTTGG
LF  CTTGTCGTCGTCGTCCTTGTAGTCACCTAGGACAGTCAGTTTGG
VH-back GACTGGTGGACAGCAAATGGGT
VH-forward GATGGCCGAGACGTTTTGGC
VL-back GTGGCAGCATTGAGGGTCGC
FLAG-R CTTGTCGTCGTCGTCCTTGTAGTC
SP6-omegaF ATTTAGGTGACACTATAGAACAACAACAACAACAAACAACAA
CAAAATGGCTAGCATGACTGGTGGACAGCAAATGGGT
McD-Linker+GCCAAAACGTCTCGGCCATCTGGTGGAGGCGGTTCAGGCGGA
GGTGGCTCTGGCGGTGGCGGATCCGGAGGTGGTGGCAGCAT
TGAGGGTCGC
McD-30-
UTR
(HisTag)
TTTTTTTTATGGTGATGGTGGTGATGGTGCAACCTGACTCG
ACTCGTACGCTTGTCGTCGTCGTCCTTGTAGTC
SP6-F ATTTAGGTGACACTATAGAACAACAACAACAACAAACAAC
McD-R
(HisTag)
TTTTTTTTATGGTGATGGTGGTGATGGTGCAACCTGACTCG
ACTCGTACG
McD-R-His ATGGTGATGGTGGTGATGGTGCAACCTGACTCGACTCGTACG
T7-long-F ATGGCTAGCATGACTGGTGGACAGCAAATGGGT
McD-
R(HisTag)-
stop
TCAATGGTGATGGTGGTGATGGTGCAACCTGACTCGACTCG
TACG
R=G or A; Y=T or C; M=A or C; K=G or T; S=G or C;
W=A or T; H=A or C or T; B=G or T or C; V=G or C or
A and D=G or A or T.
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of DNase I (Invitrogen), 40ml of EDTA-free protease
inhibitor cocktail (Nacalai tesque) and 1mM 2-mercap-
toethanol (Nacalai tesque). The cells were lyzed by sonica-
tion using a Bioruptor UCW-201 (Cosmo Bio) twice for
15min at 30-s intervals. The crude extracts were centri-
fuged for 20min at 8500r.p.m. The precipitates were
suspended in 20ml of TBS containing 8M urea and 8U
of DNase I, 40ml of EDTA-free protease inhibitor cocktail
and 1mM 2-mercaptoethanol, and then recentrifuged
for 20min at 8500r.p.m. The supernatants containing
the histidine-tagged proteins in denatured form were
immobilized on the TALON superﬂow metal aﬃnity
resin (Clontech), and the columns were washed with 10
volumes of TBS containing 10mM imidazole and 6M
urea, 10 volumes of TBS containing 1M NaCl and 10
volumes of TBS, to allow refolding of the bound proteins
on the columns. The refolded proteins were then eluted in
three fractions of 2ml TBS containing 250mM imidazole.
Subsequently, the proteins were separated by size exclu-
sion chromatography using Sephadex G-75 10/300 GL
(Amersham Biosciences) on an AKTA explorer 10S
(Amersham Biosciences) equilibrated with HBS-EP
buﬀer (10mM HEPES–NaOH, pH 7.4, 150mM NaCl,
3mM EDTA and 0.005% Tween-20) at a ﬂow rate of
0.5ml/min. The puriﬁed proteins were analyzed by SDS–
PAGE followed by staining with SimplyBlue
TM
(Invitrogen).
Construction of scFv DNA libraries
The mouse scFv DNA library was constructed as pre-
viously described by Marks et al. (2) with the following
modiﬁcations. First-strand cDNA was synthesized from
0.55mg of mouse spleen poly(A)
+ RNA (Clontech)
using immunoglobulin-speciﬁc primers MulgG1/2 for-
ward, MulgG3 forward or MuCK forward (Table 1)
with ReverTraAce (Toyobo) according to the manufac-
turer’s protocol. The products were ampliﬁed by PCR
with 0.625U of KOD-dash DNA polymerase (Toyobo)
using 2.5pmol each of 19 diﬀerent HB primers and
1.25pmol of reverse primers MulgG1/2 forward and
MulgG3 forward for VH (heavy-chain) or 18 diﬀerent
LB primers and 2.5pmol MuCK forward for VL (light-
chain) [25 cycles of 30s at 968C, 30s at 508C (for VH)o r
488C (for VL) and 1min at 728C]. Each VH and VL frag-
ment was generated by nested PCR as described above,
except for the use of an equimolar mixture of HF primers
(for VH) or an equimolar mixture of LF primers (for VL).
The resulting VH and VL genes were agarose gel-puriﬁed.
Random point mutations were further introduced into
the VH and VL fragments using a GeneMorph II Random
Mutagenesis kit (Stratagene) according to the manufac-
turer’s protocol. Brieﬂy, PCRs were performed in 100ml
volumes containing 0.04fmol of the VH or VL fragment as
a template, 2pmol each of forward and reverse primers
(VH-back and VH-forward primers for VH;V L-back
and FLAG-R primers for VL), 0.2mM dNTPs and 2U
Mutazyme II DNA polymerases (30 cycles of 30s at 958C,
30s at 588C and 1min at 728C). The resulting VH and VL
mutated genes were gel-puriﬁed.
Finally, a mouse scFv DNA library was constructed by
assembly of DNA fragments containing an SP6 promoter,
the translational enhancer from tobacco mosaic virus
(12,13), a T7 tag, the mutated VH and VL gene fragments,
a (Gly4Ser)4 linker, a FLAG-tag and poly(A) sequence
by an overlap extension PCR: 915ml volumes containing
2pmol each of VH and VL fragments, 2pmol each
of primers, SP6-omegaF, McD-linker+and McD-
30-UTR(HisTag), 0.5mM dNTPs and 5U KOD-dash
DNA polymerase (10 cycles of 30s at 968C, 30s at 588C
and 1min at 728C). The products were reampliﬁed by
PCR using 40pmol each of primers SP6-F and McD-
R(HisTag) that were added to a total volume of 1000ml
(10 cycles of 30s at 968C, 30s at 588C and 1min at 728C).
The resulting scFv DNA library was ﬁnally gel-puriﬁed.
mRNA display selection on a microfluidic chip
The biotinylated antigen proteins were immobilized on
SA sensor chips (Biacore) by passing HBS-EP buﬀer at
a ﬂow rate of 10ml/min on a Biacore 3000 instrument
(Biacore). Amounts of p53 proteins immobilized on the
chips in ﬂow cells Fc-1, Fc-2, Fc-3 and Fc-4 were 1290,
999, 1424 and 1521 RU, respectively, and those of MDM2
proteins were 677, 537, 632 and 835 RU, respectively.
The scFv DNA library was transcribed using RiboMAX
large-scale RNA production systems-SP6 (Promega) in
a total volume of 20ml containing 80mM HEPES-KOH,
pH 7.5, 2mM spermidine, 40mM DTT, 32mM MgCl2,
5mM each of ATP, CTP and UTP, 1mM GTP, 5mM
m
7G(50)ppp(50)G RNA capping analog (Invitrogen),
1pmol of scFv DNA library and 2ml of SP6 RNA poly-
merase (Promega). After transcription reaction at 378C for
3h, the DNA template was digested with DNase I
(Promega) at 378C for 1h. The resulting RNA was puriﬁed
with an RNeasy mini kit (Qiagen) and was ligated with a
PEG-puromycin spacer [p(dCp)2-T(ﬂuorescein)p-PEGp-
(dCp)2-puromycin] (11,13) using T4 RNA ligase at 158C
for 15–40h in a total volume of 50ml containing 50mM
Tris–HCl, pH 7.5, 10mM MgCl2, 12mM DTT, 1.4mM
ATP, 5% DMSO, 0.002% BSA, 40U of RNase inhibitor
(Toyobo), 0.2mM PEG-puromycin spacer, 0.6mM
PEG2000 (Nacalai tesque), 50pmol of RNA and 200U
of T4 RNA ligase (Takara). The resulting RNA-PEG-
puromycin library was puriﬁed with the RNeasy mini kit,
and could be stored at  808C for more than 1 year without
any degradation.
In vitro translation was performed in a total volume of
100ml containing 10pmol of the RNA-PEG-puromycin
library, 20ml of wheat germ cell-free extract (Zoegene),
40mg of creatine kinase and 20ml of a translation buﬀer
(Zoegene) at 268C for 5min. The reaction mixture was
subjected to gel ﬁltration on Sephadex G200 (Amersham
Biosciences) using a 0.8 4cm column (Bio-Rad) with
TBS containing 10mM EDTA, and 2-drop fractions
were collected. The ﬂuorescence of mRNA-displayed
proteins in eluate fractions was monitored with a Multi-
detection microplate reader Powerscan HT (Dainippon
Pharmaceutical). The 4th to 7th fractions containing
mRNA-displayed proteins were diluted with HBS-EP
buﬀer to 300ml and injected onto the antigen-immobilized
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258C with the Biacore 3000 using HBS-EP buﬀer at a ﬂow
rate of 20ml/min. After association for 250s and dissoci-
ation for 3000s, the sensor surfaces were washed 10 times
with HBS-EP buﬀer for 1200s. The bound molecules were
eluted competitively from the sensor surface with 7ml
of 0.1nM free antigen proteins for 1200s. Then 7mlo f
recovered solution was subjected to RT-PCR in a total
volume of 100ml containing 1mM dNTPs, 50mM Tris–
HCl, pH 8.0, 75mM KCl, 3mM MgCl2, 10mM dithio-
threitol, 200U of RNase inhibitor (Toyobo), 500U of
ReverTraAce (Toyobo) and 50pmol McD-R-His primer
(Table 1), at 508C for 30min and heated at 998C for 5min.
The RT product was ampliﬁed by PCR with KOD-plus
DNA polymerase using primers T7-long-F and McD-
R-His (24–36 cycles of 30s at 948C, 30s at 588C and
2min at 688C). DNA used for next round was recon-
structed by overlap extension PCR with KOD-plus
DNA polymerase using primers SP6-omegaF and McD-
R-His (8–12 cycles of 30s at 948C, 30s at 588C and 2min
at 688C). The resulting DNA was puriﬁed using the
Wizard PCR preps DNA puriﬁcation kit.
Finally, selected DNAs were cloned using a TOPO TA
cloning kit (Invitrogen) and sequenced with a CEQ 2000
DNA analysis system (Beckman Coulter). Genetyx-mac
13.0.10 sequence analysis software and ClustalX 1.83
were used for alignment and sequence manipulations.
In vitro evolution of a selected scFv
Random point mutations were introduced into M1-19
scFv using a GeneMorph II Random Mutagenesis kit
(Stratagene) according to the manufacturer’s protocol.
Brieﬂy, PCRs were performed in 50ml volumes containing
0.0003fmol of M1-19 scFv as a template, 1pmol each of
forward and reverse primers (T7-long-F and McD-R-His),
0.2mM dNTPs and 1U Mutazyme II DNA polymerases
(34 cycles of 30s at 958C, 30s at 588C and 1min at 728C).
The resulting mutated DNA was reconstructed by overlap
extension PCR with KOD-plus DNA polymerase using
primers SP6-omegaF and McD-R(HisTag) (8 cycles of
30s at 948C, 30s at 588C and 2min at 688C]. The resulting
mutated M1-19 scFvs were gel-puriﬁed.
In vitro transcription, translation and microﬂuidic selec-
tion were performed as described in the previous section,
with the exception that the ﬂow rate was increased to
100ml/min for on-rate selection and the washing time
was increased 20-fold for oﬀ-rate selection.
Synthesis and purification of selected scFvs
The scFv DNA template having a stop codon was ampli-
ﬁed by PCR from each cloned plasmid with KOD-plus
DNA polymerase using primers SP6-omegaF and McD-
R(HisTag)-stop (20–30 cycles of 30s at 948C, 30s at 588C
and 2min at 688C). The DNA was in vitro-transcribed
into mRNA using RiboMAX large-scale RNA production
systems-SP6 at 378C for 3h, DNase I was added, and
then incubation was continued for a further 1h at 378C.
The resulting mRNA was puriﬁed using the RNeasy mini
kit, and was in vitro-translated in the wheat germ cell-free
translation system using a dialysis cup (molecular size
cutoﬀ of 12000Da; Daiichi Pure Chemicals) at 268C
for 2–4h.
The translation products were puriﬁed on TALON
superﬂow metal aﬃnity resin with a running buﬀer
(20mM Tris–HCl buﬀer, pH 7.5, 138mM NaCl and
10mM imidazole). The columns were washed with 10
volumes of the same buﬀer, and then eluted with 1
volume of the buﬀer containing 250mM imidazole.
Subsequently, the monomeric scFvs were separated by
size exclusion chromatography using Sephadex G-75
as described above. The column was calibrated in the
HBS-EP buﬀer with standards (Amersham Pharmacia
Biotech): blue dextran 2000 (Mr 2000000), albumin
(Mr 64700), ovalbumin (Mr 45800), chymotrypsinogen
A( Mr 19900) and ribonuclease A (Mr 15400).
Pull-down assays
Streptavidin MagneSphere Paramagnetic Particles (500ml,
Promega) were incubated with 1mM of biotinylated
p53, biotinylated MDM2 or BSA-biotin (Sigma) in
500ml of TBST-BSA (20mM Tris–HCl buﬀer, pH 7.5,
138mM NaCl, 0.1% Tween-20 and 0.1% BSA) for
2–6h at 258C, and washed with TBST-BSA. The anti-
gen-immobilized beads were incubated with 5ml of trans-
lation products using wheat germ extracts in TBST-BSA.
After incubation for 1h at 258C, the beads were washed
extensively with TBST-BSA and boiled in a lithium dode-
cyl sulfate sample buﬀer (Invitrogen) containing 0.1M
DTT at 708C for 10min. ScFv proteins were separated
by SDS–PAGE on 4–12% Bis–Tris NuPAGE gels in
MES running buﬀer (Invitrogen) and transferred to a
nitrocellulose membrane using the iBlot dry blotting
system (Invitrogen). The membrane was blocked with
Blocking One Buﬀer (Nacalai tesque) in TBST (20mM
Tris–HCl buﬀer, pH 7.5, 138mM NaCl and 0.1%
Tween-20), and then probed with horseradish peroxidase
(HRP)-conjugated mouse anti-FLAG-tag monoclonal
antibody (Sigma) and an ECL western blotting kit
(Amersham Biosciences).
Competitive ELISA
Streptavidin transparent C96 plates (Nunc) were incu-
bated with 1nM biotinylated p53 or biotinylated
MDM2 in 100ml of TBST-BSA per well for 2–6h at
258C and washed with TBST-BSA. ScFvs were diluted
with blocking solution in the presence and absence of
free p53 or MDM2 protein as a competitor (1–200nM),
and incubated for 1h at 258C. Then, the protein mixture
solution (100ml) was transferred into wells on a plate with
immobilized antigen and the plate was incubated for 1h at
258C. The plate was washed ﬁve times with TBST-BSA,
then further incubated for 1h with HRP-conjugated
mouse anti-T7 tag antibody (Novagen; 1:10000 dilution
in TBST-BSA; 100ml per well). The plate was washed
ﬁve times with TBST-BSA and then 100ml of 3,30,5,
50-tetramethylbenzidine substrate (Zymed) was added per
well. The reaction was quenched with 1N HCl (100ml
per well) and the absorbance at 450nm was measured
(reference wavelength at 630nm). For each clone, the rela-
tive binding activity was calculated as the ratio of ELISA
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Western blot analysis
HEK-293 (human embryonic kidney cells) whole-cell
lysate (non-denatured) was purchased from Abnova.
Cell lysates and recombinant proteins were separated by
SDS–PAGE on 4–12% Bis–Tris NuPAGE gels in MOPS
running buﬀer (Invitrogen) and transferred to the nitro-
cellulose membrane using the iBlot dry blotting system.
The membrane was blocked with Blocking One Buﬀer in
TBST, and probed with scFv antibodies with the FLAG-
tag in TBST containing 0.1% BSA. Proteins were detected
using anti-FLAG-M2 antibody (Sigma) and goat polyclo-
nal anti-mouse IgG conjugated with alkaline phosphatase
(Bio-Rad). In a control experiment, membranes were
probed with anti-MDM2 antibody 2A10 (Abcam) and
goat polyclonal anti-mouse IgG conjugated with alkaline
phosphatase. Both membranes were visualized using
Immobilon Western AP substrate (Millipore).
Surface plasmon resonance analysis
Binding kinetics was determined by Surface plasmon
resonance (SPR) with the Biacore 3000. All experiments
were performed at 258C using TBST. Biotinylated p53
(55kDa), biotinylated MDM2 (66kDa) or BSA-biotin
was immobilized onto the SA sensor chip. The measure-
ments were performed under conditions of 390 (p53)
and 450 (MDM2) resonance units of the ligand and at a
ﬂow rate of 60ml/min. To determine dissociation
constants, three diﬀerent concentrations of the puriﬁed
monomeric scFvs, M1-19 (32kDa) and P1-93 (31kDa)
were injected. The injection periods for association and
dissociation were 60 and 300s, respectively. After each
measurement, the chip surface was regenerated with
10ml of Glycine 2.0 (Biacore), and 10mlo f5 0 m M
NaOH, 1M NaCl. The binding data were analyzed with
the 1:1 binding with mass transfer model in the
BIAevaluation software ver. 4.1 (Biacore).
Protein–DNA and protein–drug interaction analysis
Materials and methods for mRNA display selection of
DNA-binding protein complexes c-fos and c-jun and an
FK506-binding protein fkbp12 were described previously
(14,15). Brieﬂy, a mixture of three genes encoding c-Fos
(118–212 aa), c-Jun (237–334 aa) and GST (full length;
negative control), and a mixture of two genes encoding
FKBP12 (full length) and p53 (15–29 aa; negative control)
were used as model libraries. The mRNA display selection
on the SA sensor chip was performed as described
above, with the exception that biotinylated bait DNA con-
taining six repeats of the TPA-responsive element (TGAC/
GTCA) (14) or biotinylated FK506 (15) was immobilized
on the sensor chip. Amounts of DNA (Mr 60,634) immo-
bilized on the chips in ﬂow cells Fc-1, Fc-2, Fc-3 and Fc-4
were 1314, 1433, 1920 and 1874 RU, respectively, and
those of FK506 (Mr 1066) were 683, 650, 655 and 600
RU, respectively.
RESULTS
In vitro selection of antibodies from a naı¨ve scFv library
The mRNA display selection of scFv was performed on a
Biacore microﬂuidic chip (Figure 1) as described in the
Materials and methods section. Since the diversity of the
mouse scFv library prepared from mouse spleen poly A
+
RNAs is estimated to be 10
6–10
8, while mRNA display
allows screening of  10
12 molecules, we also introduced
random point mutations into the scFv library. We chose
p53 (human tumor suppressor protein) and MDM2
(human murine double minute) proteins as model antigens
that were immobilized on the Biacore sensor chip. The
selection experiment was performed on the microﬂuidic
chip, and selected scFv genes were ampliﬁed by reverse
transcription (RT)-PCR and identiﬁed by cloning and
sequencing. Unexpectedly, the recovered anti-p53 and
anti-MDM2 scFv sequences converged on a single
sequence and two sequences, respectively, after only two
rounds of selection. These clones revealed high aﬃnity,
but also low antigen speciﬁcity, in pull-down assays
(data not shown), and so we examined the clones after a
single round of selection in each case (35 clones for anti-
p53 and 25 clones for anti-MDM2). When the binding
activities of 29 (anti-p53) and 20 (anti-MDM2) clones
with distinct sequences were examined by pull-down
assays, P1-93 and M1-19 showed high speciﬁcity against
the respective antigens among p53, MDM2 and BSA
(Figure 2A). The amino acid sequences of P1-93 and
M1-19 are shown in Figure 2B. In competitive ELISA,
both clones dose-dependently inhibited the ELISA signal
(Figure 2C), and Scatchard plots revealed that the KDso f
P1-93 and M1-19 were 22 and 5.9nM, respectively. The
KDs of P1-93 and M1-19 were also determined by SPR as
Figure 1. Schematic representation of the mRNA display selection of
scFv on a microﬂuidic chip. Step (1): an scFv DNA library is tran-
scribed to mRNA in vitro. Step (2): the mRNA library is ligated with a
PEG-puromycin spacer. Step (3): the RNA-PEG-puromycin library is
translated in a cell-free translation system. Step (4): the mRNA-
displayed scFv library is injected into a sensor chip on which a target
antigen is immobilized. Step (5): the bound scFv is eluted competitively
with the free antigen. Step (6): the RNA is ampliﬁed by RT-PCR and
used for the next round of selection or cloning and sequencing.
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obtained by the two diﬀerent methods are similar.
In vitro evolution of scFv
Further, we performed in vitro evolution of scFv with
higher aﬃnity against MDM2 from a randomly mutated
M1-19 scFv library. We applied on-rate and oﬀ-rate selec-
tion as a selection pressure for in vitro aﬃnity maturation
with the Biacore instrument: the on-rate selection was
performed by controlling ﬂow rate, and the oﬀ-rate
selection was carried out by using a prolonged washing
process on the sensor chip. After one round of selection,
the recovered scFv genes were cloned and sequenced, and
the KDs were evaluated by competitive ELISA (Figure 3A
and D). We obtained four mutants with higher aﬃnity for
MDM2 (KD=0.7–3.8nM) than the progenitor M1-19
from 22 distinct clones. The strongest binder M1-19a
was conﬁrmed to have a higher on-rate and lower oﬀ-
rate than M1-19 by SPR (Figure 3B) and was also con-
ﬁrmed to recognize only antigen protein MDM2 in crude
cell lysates by western blotting (Figure 3C). These results
Figure 2. The selected scFvs anti-p53 P1-93 and anti-MDM2 M1-19. (A) Pull-down assays of the anti-p53 scFv P1-93 (top) and anti-MDM2 scFv
M1-19 (bottom) using p53-, MDM2- or BSA-immobilized beads. Recovered scFv with FLAG-tag was detected with the anti-FLAG antibody.
(B) Predicted amino acid sequences of the VH (black bar) and VL (gray bar) regions of anti-p53 scFv P1-93 and anti-MDM2 scFv M1-19.
Residue numbering is according to Kabat et al. (20) (C) Competitive ELISA. P1-93 or M1-19 was preincubated with a competitor (0–200nM
free antigen) and allowed to bind to antigen-immobilized plates. After washing, remaining scFvs were detected with the anti-T7 tag antibody.
(D) Biacore sensorgrams of the puriﬁed P1-93 (left; 31kDa) and M1-19 (right; 32kDa) using a p53- (blue lines; 55kDa) or MDM2-immobilized
(red lines; 66kDa) sensor chip. The measurements were performed under conditions of 450 RU of the ligand and at a ﬂow rate of 60ml/min.
To determine dissociation constants, three diﬀerent concentrations (35, 64 and 136nM for P1-93 and 27, 50 and 75nM for M1-19) of the monomeric
scFvs were injected.
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and speciﬁcity for practical use. Although the mutations
of the selected scFvs were distributed among the whole
sequences and no ‘consensus’ mutations were identiﬁed,
the mutation Y100bH within VH CDR3 may contribute
to the improved aﬃnity and speciﬁcity, because this region
is usually important for binding with antigens.
Ultrahigh efficiencies of protein selection
Surprisingly, our results indicated that the positive clone
was eﬃciently enriched through only one or two rounds
of selection from the large library containing  10
12
molecules, implying ultrahigh eﬃciency of the method.
To estimate the enrichment eﬃciency, we performed
model experiments using a mixture of two kinds of scFv
genes. The P1-93 (anti-p53) or M1-19 (anti-MDM2) gene
was mixed with an anti-ﬂuorescein scFv gene (5) (‘Flu’ as
a negative control) at a ratio of 1:10
2, 1:10
4, 1:10
6 or 1:10
8,
and subjected to one round of mRNA display selection
on the sensor chip. The selection of the 1:10
6 mixture of
P1-93:Flu genes and the 1:10
8 mixture of M1-19:Flu genes
each resulted in a roughly 1:1 ﬁnal gene ratio (Figure 4A),
indicating enrichment eﬃciencies of 10
6- and 10
8-fold per
round, respectively.
Since we have applied mRNA display to screening of
protein–protein (13), protein–DNA (14) and protein–drug
(15) interactions so far, it is interesting whether the ultra-
high eﬃciency by the combination of mRNA display and
Figure 3. In vitro evolution of anti-MDM2 scFv M1-19. (A) Dissociation constants (KDs) of M1-19 (red circle) and the four mutant scFvs
(green circles) were obtained by means of Scatchard plots of the data from competitive ELISA. (B) Biacore sensorgrams of the mutant M1-19a
(amount of immobilized antigen was 450 RU). M1-19a had a higher on-rate and lower oﬀ-rate (ka=2.5 10
5/Ms, kd=8.6 10
5/s, KA=3.0 10
9/
M, KD=0.34nM) than the progenitor M1-19 (ka=5.5 10
4/Ms, kd=2.3 10
4/s, KA=2.4 10
8/M, KD=4.3nM; Figure 2D, right, red lines).
(C) Recombinant p53 and MDM2 proteins (10 and 25ng), and HEK-293 cell lysates (1 and 2.5mg) were analyzed by western blotting using M1-19a
(left) or commercially available anti-MDM2 2A10 (right) as a control, respectively. (D) Predicted amino acid sequences of the VH (black bar) and
VL (gray bar) regions of the mutant scFvs M1-19a-d. Residue numbering is according to Kabat et al. (20).
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Consequently, we conﬁrmed that not only protein–protein
(antigen–antibody) interactions, but also protein–DNA
and protein–drug interactions were selected by our
method with high-enrichment eﬃciencies of >10
6-fold
(Figure 4B and C). Since the enrichment eﬃciencies of
these model experiments with a usual agarose resin were
only 10- to 10
3-fold per round [Refs (14) and (15); data not
shown], the enrichment eﬃciency was improved 10
3-t o
10
5-fold over previous methods.
DISCUSSION
Although Biacore instruments have so far been utilized
mainly to analyze biomolecular interactions by SPR,
afewresearchers haveusedthis approachtoﬁshforaﬃnity
targets from a randomized DNA library (16), phage-
displayed protein libraries (17,18) or a ribosome-displayed
antibody library (19). However, the enrichment eﬃciency
in these applications was not high. Why, then, was ultra-
high eﬃciency achieved in the present protein selection
by mRNA display? The mRNA-displayed protein is a rel-
atively small object pendant from its encoding RNA
moiety, which is about 10 times larger. Thus, nonspeciﬁc
adsorption of RNA on solid surfaces is potentially sig-
niﬁcant. The matrix of the Biacore sensor chip consists
of carboxymethylated dextran covalently attached to a
gold surface, and poorly binds nucleic acid molecules,
because both materials are negatively charged. In contrast,
phage display and ribosome display involve large pro-
tein moieties (coat proteins or ribosome), so the use of
the sensor chip may not improve the enrichment eﬃciency
in these cases.
It should be noted that the ultrahigh enrichment eﬃ-
ciency made it diﬃcult to set the number of selection
rounds at a level that is appropriate to remove all non-
binders as well as to pick all binders with various aﬃnities
from a library. If the number of selection rounds is too
small, many negative sequences will be cloned; on the
other hand, excess rounds of selection will yield only a
single sequence with the highest aﬃnity. In this study,
we obtained 20–30 diﬀerent sequences, including P1-93
and M1-19, with high antigen speciﬁcity after a single
round of selection, while we obtained only one or two
negative sequences with high aﬃnity but low antigen spe-
ciﬁcity from 10
6–10
8 library after two (probably excess)
rounds of selection (>10
12-fold).
In summary, we achieved ultrahigh eﬃciencies
(10
6–10
8-fold per round) of protein selection by mRNA
display with the microﬂuidic system. We obtained scFvs
with high aﬃnity and speciﬁcity from a naı¨ve library by
mRNA display selection for the ﬁrst time. It took only
three days to perform each selection experiment, including
activity evaluation by ELISA. Although preparation of
target materials of high quality is required, we anticipate
this simple method to be a starting point for a versatile
system to facilitate high-throughput preparation of mono-
clonal antibodies for analysis of proteome expression
and detection of biomarkers, high-throughput analysis
of protein–protein, protein–DNA and protein–drug inter-
actions in proteomic and therapeutic ﬁelds, and rapid evo-
lution of novel artiﬁcial proteins from large randomized
libraries that often require 10 or more rounds of selection.
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